DISCOVER
CEREBRAL VASOSPASM COMMON AND DEADLY
1 in 10000 People experience an aneurysm rupture every year. Up to 70% of these patients have to cope with cerebral vasospasm, the most common complication of aneurysmal Sub arachnoid haemorrhage (a-SAH) as well as the leading cause of delayed morbidity and mortality.
WITH NEW TREATMENT OPTIONS VASOSPASM COULD BE REVERSIBLE
Cerebral vasospasm is a life-threatening narrowing of brain vessels that typically transpires 7 to 10 days after an aSAH. The severe narrowing restricts blood flow to the affected area, leading to delayed cerebral ischemia and a poor neurological prognosis for those who suffer it.
However today, with advances in technology and new treatment pathways, cerebral vasospasm could be reversible.
Discover NEVA VS SPECIFICALLY TAILORED TO VASOSPASM TREATMENT
NeVa VS combines a smooth and continuous architecture and the deliverability of a stent retriever and an enhanced outward radial force to effectively dilate critically narrowed vessels.
EXPANSION OPTIMIZED
FLOW MAINTAINEDNeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture. It combines a smooth and continuous architecture and the deliverability of a stent retriever with an enhanced outward radial force to effectively dilate critically narrowed vessels.
SPECIFIC
Designed for vasospasm:
- Optimized vessel expansion
- Distal flow maintained during treatment
SAFE
No vessel ruptures observed*
PROCEDURAL SUCCESS
86.5% of procedural success with an average of 1.3 deployments per vessel*
93.2% of vessels required no further treatment*
*in the VITAL study
NeVa VS Vital Study
Proven SafetyThe VITAL clinical trial, recently published in the Journal of Interventional Surgery, confirms NeVa VS to be a safe treatment for Cerebral Vasospasm after aSAH.
0
approved for use
in the U.s.
NeVa VS is the first and only FDA HDE approved device for the adjunct treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage.
Approved by FDA under HDE 210004. Note: The effectiveness of this device for this use has not been demonstrated”